Disparity in Quality of Infectious Disease vs Addiction Care Among Patients With Injection Drug Use-Associated Staphylococcus aureus Bacteremia.

• Type of Material: Article
• Authors: David Phillip Serota, Emory University; Emily D. Niehaus, Emory University; Marcos C. Schechter, Emory University; Jesse Thomas Jacob, Emory University; Jeb Jones, Emory University; Susan M Ray, Emory University; Colleen Kelley, Emory University; Russell Ryan Kempker, Emory University
• Language: English
• Date: 2019-07
• Publisher: Oxford University Press (OUP)
• Publication Version: Final Published Version
• Copyright Statement: © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1093/ofid/ofz289
• Title of Journal or Parent Work: Open Forum Infectious Diseases
• ISSN: 2328-8957
• Volume: 6
• Issue: 7
• Start Page: ofz289
• End Page: ofz289
• Grant/Funding Information: Dr. Serota receives grant funding from the Georgia Clinical and Translational Science Alliance (UL1TR002378 and TL1TR002382).; This work was unfunded.
• Keywords: endocarditis; bacteremia; substance use disorder; injection drug use; Staphylococcus aureus
• Research Categories: Health Sciences, Epidemiology; Health Sciences, Public Health

Abstract

Evidence-based interventions for Staphylococcus aureus bacteremia (SAB) are well known, but it is unclear how they are implemented among patients with injection drug use-associated (IDU) SAB. Of 46 patients with IDU-SAB identified, all received high-quality SAB management; however, few received appropriate recognition or treatment of their underlying substance use disorder.